AS 202
Alternative Names: AS-202; TAK-212Latest Information Update: 28 Oct 2024
At a glance
- Originator AcuraStem
- Class Antidementias; Antisense oligonucleotides
- Mechanism of Action PIKFYVE protein inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Amyotrophic lateral sclerosis; Frontotemporal dementia
Highest Development Phases
- No development reported Amyotrophic lateral sclerosis; Frontotemporal dementia
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Amyotrophic-lateral-sclerosis in USA (Intrathecal)
- 28 Oct 2024 No recent reports of development identified for preclinical development in Frontotemporal dementia in USA (Intrathecal)
- 25 Sep 2023 Takeda in-licenses PIKFYVE targeted therapeutics from AcuraStem